Table 4.

Comparison of phase I designs under dose-toxicity Scenario 3.

Dose	DLT rate	Designs
		3 + 3	3 + 3@9,2	CS(40; 3,6,9)	CS(25; 5,11)	CS(35; 2,6)	CS(50; 1,3,5)	CS(50)	mTPI	mTPI2	CRM
Proportion of recommended dose (MTD) levels (%)
0		10	11	9	26	7	0	2	0	0	0
1	0.10	9	9	8	17	7	2	2	6	3	2
2	0.10	8	9	7	15	7	2	2	7	10	5
3	0.10	7	12	6	12	8	1	1	14	15	6
4	0.10	30	39	31	23	32	13	13	26	20	21
5	0.25	36	20	39	6	38	76	80	45	46	58
6	0.80	0	0	0	0	0	4	0	1	6	8
7	0.90	0	0	0	0	0	0	0	0	0	0
Proportion of patients treated (%)
1	0.10	29	28	26	47	23	11	9	27	27	11
2	0.10	19	18	17	22	18	10	8	23	24	7
3	0.10	16	15	15	14	16	11	8	20	20	8
4	0.10	16	20	19	11	19	15	14	16	16	22
5	0.25	15	16	19	5	19	33	46	11	11	38
6	0.80	4	4	4	0	5	18	14	2	2	10
7	0.90	0	0	0	0	0	2	2	0	0	4
Average number of patients		18.2	22	23.5	24.0	17.2	13.3	19.0	18.0	18.0	18.0
Percent toxicity (%)		20.0	19.4	18.7	17.5	19.2	30.1	29.1	13.2	13.2	26.2